Profile: Eyenovia Inc (EYEN.A)
15 Aug 2019
Eyenovia, Inc., incorporated on July 23, 2014, is a clinical stage biopharmaceutical company. The Company is engaged in developing a pipeline of micro-doses therapeutics products utilizing its patented piezo-print delivery technology. Eyenovia’s pipeline is focused on the late-stage development of microdosed medications for mydriasis, myopia progression, glaucoma, and other eye diseases. The Company’s products are MicroStat, MicroPine, MicroProst and MicroTears.
MicroStat is a combination micro-formulation product (phenylephrine-tropicamide) candidate for pharmacologic mydriasis (eye dilation). The Company is developing MicroStat to improve efficacy, usability and tolerability of pharmacologic mydriasis. MicroPine is topical treatment for progressive myopia, a back-of-the-eye disease. MicroProst is proprietary latanoprost formulation product candidate, which is being developed for the reduction of IOP in patients with Chronic Angle Closure Glaucoma (CACG), as well as Primary Open Angle Glaucoma (POAG) and Ocular Hypertension. MicroTears is a micro-droplet ocular hyperemia (red eye), pruritis (itch) and ocular lubrication product.
The Company competes with Akorn, Inc. and Alcon, Inc.
295 Madison Ave Ste 2400
NEW YORK NY 10017-6434